Long-acting amylin analogue, often paired with semaglutide as CagriSema.
Typical dose range: 0.16–2.4 mg
Frequency: Weekly
Route: Subcutaneous
Half-life: ~7 days
Evidence level: Phase 3
Amylin analogue that complements GLP-1 mechanisms. Most users only encounter it as part of the CagriSema stack.